Journal of Long-Term Effects of Medical Implants

ISSN for PRINT: 1050-6934

For Online Access

Best Paper Award Selection - Editorial Board Site

2006, Volume16

Issue 2

104 pages

Issue price - $189.00

Richard Visconti, PhD
Medical University of South Carolina, Charleston, South Carolina, USA

Vladimir Mironov, MD, PhD
Director, Shared Tissue Engineering Lab., Department of Cell Biology and Anatomy Medical University of South Carolina 173 Ashley Avenue, Suite 601 Charleston SC 29425

Vladimir A. Kasyanov, DSc, PhD
Riga Stradins University, Riga, Latvia

Michael J. Yost, PhD
University of South Carolina, Columbia, South Carolina, USA

Waleed Twal, PhD
Medical University of South Carolina, Charleston, South Carolina, USA

Thomas Trusk, PhD
Medical University of South Carolina, Charleston, South Carolina, USA

Xuejun Wen
Medical University of South Carolina, Charleston, South Carolina, USA

Iveta Ozolanta, MD, PhD
Riga Stradins University, Riga, Latvia

Arnolds Kadishs, MD
Riga Stradins University, Riga, Latvia

Glenn D. Prestwich
Department of Medicinal Chemistry, 30 South 2000 East, Room 201, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112-5820, U.S.A.

Louis Terracio, PhD
New York University Medical Center, New York, New York, USA

Roger R. Markwald, PhD
Medical University of South Carolina, Charleston, South Carolina, USA

Tissue engineering is a fast-evolving field of biomedical science and technology with future promise to manufacture living tissues and organs for replacement, repair, and regeneration of diseased organs. Owing to the specific role of hemodynamics in the development, maintenance, and functioning of the cardiovascular system, bioreactors are a fundamental of cardiovascular tissue engineering. The development of perfusion bioreactor technology for cardiovascular tissue engineering is a direct sequence of previous historic successes in extracorporeal circulation techniques. Bioreactors provide a fluidic environment for tissue engineered tissue and organs, and guarantee their viability, maturation, biomonitoring, testing, storage, and transportation. There are different types of bioreactors and they vary greatly in their size, complexity, and functional capabilities. Although progress in design and functional properties of perfusion bioreactors for tissue engineered blood vessels, heart valves, and myocardial patches is obvious, there are some challenges and insufficiently addressed issues, and room for bioreactor design improvement and performance optimization. These challenges include creating a triple perfusion bioreactor for vascularized tubular tissue engineered cardiac construct; designing and manufacturing fluidics-based perfused minibioreactors; incorporation of systematic mathematical modeling and computer simulation based on computational fluid dynamics into the bioreactor designing process; and development of automatic systems of hydrodynamic regime control. Designing and engineering of built-in noninvasive biomonitoring systems is another important challenge. The optimal and most efficient perfusion and conditioning regime, which accelerates tissue maturation of tissue-engineered constructs also remains to be determined. This is a first article in a series of reviews on critical elements of cardiovascular tissue engineering technology describing the current status, unsolved problems, and challenges of bioreactor technology in cardiovascular tissue engineering and outlining future trends and developments.

Download article, 111-130 pages

Article price - $35.00

  Next article >>